2Micallef IN,Chhanabhai M,Gascoyne RD,et al.Lymphoproliferative disorders following allogeneic bone marrow transplantation:the Vancouver experience.Bone Marrow Transplant,1998,22:981-987.
4Heslop HE.How I treat EBV lymphoproliferation.Blood,2009,114:4002-4008.
5Burnsa DM,Crawfordb DH.Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.Blood Rev,2004,18:193-209.
6Choquet S,Leblond V,Herbrecht R,et al.Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:results of a prospective multicenter phase 2 study.Blood,2006,107:3053-3057.
7Rooney CM,Smith CA,Ng CY,et al.Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.Blood,1998,92:1549-1555.
8Weinstock DM,Ambrossi GG,Brennan C,et al.Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplantation lymphoproliferative disorder after hematopoietic stem cell transplant:an approach in development.Bone Marrow Transplant,2006,37:539-546.
9Heslop HE,Ng CY,Li C,et al.Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.Nat Med,1996,2:551-555.
10Steven NM,Leese AM,Annels NE,et al.Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory.J Exp Med,1996,184:1801-1813.
